OMass Therapeutics

OMass Therapeutics is a biotechnology company located in Oxford, UK, focused on discovering and developing novel small molecule medicines for rare diseases and immunological conditions.

Founded in 2016 as a spin-out from Oxford University by Prof. Dame Carol Robinson and others, OMass utilizes advanced techniques like native mass spectrometry and custom chemistry to study complex biological targets in their natural environments. The company operates at the pre-clinical stage and has developed a proprietary drug discovery platform called OdyssIONTM, which allows for high-resolution analysis of protein interactions. This platform helps identify drug candidates that can effectively modulate complex formations. OMass is also engaged in collaborations with major pharmaceutical companies, including an exclusive agreement with Genentech to develop therapies for inflammatory bowel disease. With a strong focus on addressing high unmet medical needs, OMass aims to provide innovative solutions for patients suffering from rare immunological and genetic disorders.